GLOBAL EXPERT EXCHANGE

Wednesday, January 28, 2015

Catheter-based treatment of hypertension, heart failure and beyond – where do we stand, where do we go?

CHAIRMAN:
Felix Mahfoud
Horst Sievert
MODERATOR:
Thomas Zeller
Paul Sobotka
Roland Schmieder
Michael Böhm
Oliver Vonend

08:00 – 08:07 Renal denervation: what has anatomy taught us?
Renu Virmani

08:07 – 08:14 From bench to bedside: how and where to treat the renal artery?
Felix Mahfoud

08:14 – 08:21 How does renal artery anatomy affect the outcome of RDN procedures?
Britta Vogel

08:21 – 08:28 What to learn from recent clinical trials: Symplicity HTN-3, FRENCH-DENERV-HTN, PRAGUE-15?
Thomas Zeller

08:28 – 08:35 Renal denervation – dead or alive? The view point of a nephrologist/hypertension specialist
Oliver Vonend

08:35 – 08:42 Recent clinical findings and how they changed my patient selection: who is the ideal candidate?
Philipp Lurz

08:42 – 08:49 What is needed now? New clinical trials that would change my clinical practice
Roland Schmieder

08:49 – 08:56 Renal denervation in patients with impaired kidney function – results from the Heidelberg RDN registry
Erwin Blessing

08:56 – 09:03 Late results of radiofrequency denervation and assessment of vessel patency
Yvonne Bausback

We are asking all faculty members to strictly respect the given time limits.
**Wednesday, January 28, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:03 – 09:10</td>
<td>Preliminary results of RETREAT (renal denervation with ultrasound after failed radiofrequency denervation) Horst Sievert</td>
</tr>
<tr>
<td>09:10 – 09:17</td>
<td>Going to the source: A disruptive approach to renal denervation with the non-vascular Verve system Richard Heuser</td>
</tr>
<tr>
<td>09:17 – 09:24</td>
<td>Turn the page for hypertension and let's go for heart failure and arrhythmias               Michael Böhm</td>
</tr>
<tr>
<td>09:24 – 09:31</td>
<td>Blood pressure-lowering interventions beside renal denervation – what is on the horizon? Horst Sievert</td>
</tr>
<tr>
<td>09:31 – 09:38</td>
<td>Treatment of resistant hypertension by creation of an AV anastomosis: the pathophysiological basis and principle of treatment Paul Sobotka</td>
</tr>
<tr>
<td>09:38 – 09:45</td>
<td>Orchestrating sympathovagal balance with Barostim                                          Navid Madershahian</td>
</tr>
<tr>
<td>09:45 – 09:52</td>
<td>Barostim: Clinical evidence in resistant hypertension and heart failure                      Jochen Müller-Ehmsen</td>
</tr>
<tr>
<td>09:52 – 10:00</td>
<td>Discussion and conclusion</td>
</tr>
</tbody>
</table>

*We are asking all faculty members to strictly respect the given time limits.*
Wednesday, January 28, 2015

MAIN ARENA 1

15:00 – 16:30 VIVA @ LINC: Renal and visceral disease: pressing new dilemmas and pushing the field forward

CHAIRMAN:
Chris Metzger
MODERATOR:
Michael Jaff
Tony Das
Peter Schneider
Felix Mahfoud
Michael Moche
Jos van den Berg
Henrik Schröder

15:00 – 15:05 Introduction by the chairman
15:05 – 15:13 CORAL trial aftermath: What do we do now? Renal revascularisation in perspective
Michael Jaff
15:13 – 15:33 Live case transmission from Teaneck
15:33 – 15:41 How to assess the hemodynamic importance of a renal artery stenosis
Felix Mahfoud
15:41 – 15:49 Endovascular treatment of mesenteric angina: Tips, tricks, and techniques
Chris Metzger
15:49 – 16:14 Live case transmission from Teanec
16:14 – 16:22 Visceral artery aneurysms. The silent killer comes into focus now that we can find them and fix them
Michael Dake
16:22 – 16:30 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.
Thursday, January 29, 2015

**MAIN ARENA 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:37 – 13:42</td>
<td>Review of results of the European, randomized trial of AV anastomosis with the ROX coupler for resistant hypertension</td>
<td>Paul Sobotka</td>
</tr>
<tr>
<td>13:42 – 14:03</td>
<td>Live case transmission from Leipzig Heartcenter</td>
<td></td>
</tr>
<tr>
<td>14:03 – 14:10</td>
<td>The role of TAVI in high-risk and normal-risk patients</td>
<td>Joachim Schofer</td>
</tr>
<tr>
<td>14:10 – 14:17</td>
<td>Echocardiographic criteria for favourable TAVI outcome – can we predict the risk?</td>
<td>Andreas Hagendorff</td>
</tr>
<tr>
<td>14:17 – 14:22</td>
<td>Cerebral protection during TAVI – the CLEAN-TAVI trial</td>
<td>Stephan Haußig</td>
</tr>
<tr>
<td>14:22 – 14:41</td>
<td>Live case transmission from Leipzig</td>
<td></td>
</tr>
<tr>
<td>14:48 – 14:55</td>
<td>Current status of ablation therapy for atrial fibrillation</td>
<td>Philipp Sommer</td>
</tr>
<tr>
<td>14:55 – 15:00</td>
<td>Discussion and conclusion</td>
<td></td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.